Cerus (NASDAQ:CERS) Issues Quarterly Earnings Results

Cerus (NASDAQ:CERS) released its earnings results on Thursday. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01, Zacks reports. Cerus had a negative net margin of 19.27% and a negative return on equity of 58.65%. The company had revenue of $45.08 million for the quarter, compared to the consensus estimate of $42.50 million. During the same period in the prior year, the company posted ($0.07) EPS.

Cerus Trading Up 15.0 %

NASDAQ CERS traded up $0.31 on Friday, reaching $2.35. The company had a trading volume of 3,050,415 shares, compared to its average volume of 1,273,192. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.41 and a quick ratio of 1.72. Cerus has a fifty-two week low of $1.21 and a fifty-two week high of $2.85. The business has a 50 day moving average of $1.93 and a two-hundred day moving average of $1.94. The firm has a market cap of $433.57 million, a price-to-earnings ratio of -13.94 and a beta of 1.20.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on CERS shares. Craig Hallum began coverage on shares of Cerus in a research report on Friday, April 12th. They set a “buy” rating and a $5.00 price objective for the company. Cantor Fitzgerald lifted their price target on Cerus from $3.00 to $4.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.